Supplementary Table S2 from FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation

Authors:

Open Access

The list of preferred terms included in grouped terms used for safety analysis in ASCEMBL